Cytokine receptors for Interleukin-4, Interleukin-8, Interleukin-13, Interleukin-17, Tumor necrosis factor-alpha, and Interferon-alpha

This target entry represents a heterogeneous collection of cytokine receptors that are pivotal in mediating inflammatory and immune signaling pathways. It encompasses the Interleukin-4 receptor (IL-4R), Interleukin-8 receptors (CXCR1 and CXCR2), Interleukin-13 receptor (IL-13R), Interleukin-17 receptor (IL-17R), Tumor Necrosis Factor receptors (TNFR1 and TNFR2), and the Type I Interferon receptor (IFNAR). These receptors belong to diverse structural classes, including Type I and II cytokine receptors, G protein-coupled receptors, and the TNF receptor superfamily (Source: Nature Reviews Immunology, 2018). They are central to the pathogenesis of various autoimmune and chronic inflammatory conditions such as asthma, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus (Source: Lancet, 2021). Therapeutic intervention typically involves monoclonal antibodies that block ligand-receptor interactions or small molecule inhibitors that disrupt downstream signaling (Source: Journal of Clinical Investigation, 2019). While these therapies are highly effective, they are associated with safety concerns such as systemic immunosuppression and an increased susceptibility to opportunistic infections (Source: New England Journal of Medicine, 2020).

Other names

Interleukin-4 receptorInterleukin-8 receptorInterleukin-13 receptorInterleukin-17 receptorTumor necrosis factor receptorInterferon-alpha receptorIL-4RIL-8RIL-13RIL-17RTNFRIFNARCXCR1CXCR2

Monoclonal antibody-mediated blockade of receptor subunits, competitive antagonism of G protein-coupled receptors, and decoy receptor-mediated ligand sequestration.